<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265366</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/12</org_study_id>
    <nct_id>NCT03265366</nct_id>
  </id_info>
  <brief_title>Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses</brief_title>
  <acronym>ABPA-MR</acronym>
  <official_title>Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the concordance between chest computerized tomography-scan
      (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen
      in Allergic BronchoPulmonary Aspergillosis (ABPA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ABPA is responsible for pulmonary exacerbations in chronic bronchial diseases. The
      treatment of ABPA consists in systemic corticosteroids and anti fungal therapy, which can
      have severe side effects. The diagnosis is difficult, based on several but non-specific
      characteristics. One of the radiologic abnormalities on CTscan could be more specific : high
      attenuation in impacted mucus, but this sign is found in about 30% of cases. Recent articles
      and investigators experience seem to demonstrate that MRI could provide an interesting tool
      for ABPA diagnosis, studying the signal of bronchial impactions. The aim of the study is to
      describe the MRI characteristics of patients with ABPA and compare the results with those
      obtained by CTscan, and in order to determine if there is a specific signal of impaction in
      ABPA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between chest CT scan and MRI for bronchial and pulmonary signs of ABPA (bronchiectases, infiltrates, impactions)</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured by a kappa test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Allergic Bronchopulmonary Aspergilloses</condition>
  <arm_group>
    <arm_group_label>ABPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 patients with ABPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe asthma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 patients with severe asthma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.</description>
    <arm_group_label>ABPA</arm_group_label>
    <arm_group_label>Severe asthma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CT scan (standard reference)</intervention_name>
    <description>It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.</description>
    <arm_group_label>ABPA</arm_group_label>
    <arm_group_label>Severe asthma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  study patients have a diagnosis of ABPA

          -  control patients have severe asthma

          -  All the patients are ≥ 18 years old, have social security care, signature of consent
             form

        Exclusion Criteria:

          -  cystic fibrosis

          -  other type of aspergilloses

          -  contraindication for MRI

          -  woman without effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie MACEY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie MACEY, MD</last_name>
    <phone>(0)5 57 62 32 90</phone>
    <phone_ext>+33</phone_ext>
    <email>julie.macey@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rkia ACHKIR</last_name>
    <phone>(0)5 56 79 56 79</phone>
    <phone_ext>+33</phone_ext>
    <email>rkia.achkir@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie MACEY, MD</last_name>
      <phone>(0)5 57 62 32 90</phone>
      <phone_ext>+33</phone_ext>
      <email>julie.macey@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rkia ACHKIR</last_name>
      <phone>(0)5 56 79 56 79</phone>
      <phone_ext>+33</phone_ext>
      <email>rkia.achkir@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Julie MACEY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François LAURENT, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaël DOURNES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal RAHERISON-SEMJEN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie BLANCHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire DROMER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier DEMANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ultrashort echo time magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Aspergillosis, Allergic Bronchopulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

